MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

From Medicineworld.org: Screening Newborn for 'Bubble Boy Disease'

Health news Asthma Hypertension  


Do You Read All Of Our Cancer Blogs?

Do You Read All Of Blogs?
Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.

Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.

Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.

Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.

Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.

Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.

Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.

Janet      

Screening Newborn for 'Bubble Boy Disease'


Screening  Newborn for 'Bubble Boy Disease'
Two new UCLA studies show that newborn screening for Severe Combined Immunodeficiency (SCID) - a rare, treatable disorder of the immune system usually known as "bubble boy disease" - is both cost-effective and could be done accurately using a two-tiered testing method.

"We wanted to determine whether testing for SCID should be added to the universal screening panel for inherited disorders," said Dr. Sean McGhee, clinical instructor of pediatric immunology at Mattel Children's Hospital at UCLA. "Treatment is now advanced enough that 95 percent of children can be cured, but newborns must be detected in the first month, before the onset of severe infections".

In the first study - detailed in the November edition of the Journal of Pediatrics - UCLA scientists concluded that SCID screening could result in a large benefit to infants, making screening relatively cost-effective in spite of the low incidence of the disease. However, an adequate test would be critical to cost-effectiveness.

The analysis is the first of its kind to examine formally cost and benefits of SCID newborn screening.

To conduct the study, scientists used information about the costs of diagnosing and treating SCID and the benefits of early diagnosis, and performed a cost-benefit analysis comparing universal screening with screening only those with a family history of SCID.

Scientists determined that a SCID screening test that cost less than five dollars with a false-negative rate of 0.9 percent and a false-positive rate of 0.4 percent would be considered cost-effective by most currently accepted standards.

A nationwide screening program would cost an additional $23.9 million per year for screening costs, but would result in 760 years of life saved per year of screening.

In a related pilot study - described in the December edition of Molecular Genetics and Metabolism - McGhee and colleagues looked at using a "two-tiered" strategy to improve the accuracy of SCID screenings.

"Existing tests for SCID are pretty good by themselves, but they do not provide sufficient accuracy in diagnosing the disorder to make them cost-effective," McGhee said. "We wanted to see if combining the two tests would limit the false positive results".

The current basis for the screening test is measurement of the number of lymphocytes at the time of birth that are normally very high, but very low in SCID infants. The screening is done by using dried blood samples obtained for other newborn screenings.

In the retrospective analysis, investigators measured serum or plasma levels of interleukin-7 (IL-7), a T-cell growth cytokine elevated in SCID, in combination with the previously developed T-cell receptor recombination excision circles assay.

They found that combining the tests in a two-tiered strategy decreased the false positive rate to nearly zero, which would be sufficient to allow cost-effective screening.

McGhee added that this strategy should be addressed in a multi-center, prospective trial to determine accurately the incidence, specificity, sensitivity and cost of SCID newborn screening.

The incidence of SCID is unknown but may be more common than published estimates because infants frequently die of infection before diagnosis. If an infant is diagnosed - preferably within the first month of life - and before their first infection, most can be treated with a bone-marrow transplant. About half of the patients can be cured; the other half may require intravenous immune globulin treatment therapys, but can live normal lives.

Other UCLA authors on both studies included Dr. E. Richard Stiehm and Dr. Edward McCabe. In addition, Dr. Morton Cowan, University of California, San Francisco, and Dr. Paul Krogstad, UCLA, co-authored the study on the two-tiered universal newborn screening strategy.

Support for all research was provided by the human and molecular development training grant at the David Geffen School of Medicine at UCLA, NIH/NICHD and the Culpepper Biomedical Pilot Initiative of the John D. Rockefeller Foundation.

McCabe is an adviser to GeneFluidics, a nanotechnology company involved in genetic testing.


Source: UCLA


Did you know?
Two new UCLA studies show that newborn screening for Severe Combined Immunodeficiency (SCID) - a rare, treatable disorder of the immune system usually known as "bubble boy disease" - is both cost-effective and could be done accurately using a two-tiered testing method. "We wanted to determine whether testing for SCID should be added to the universal screening panel for inherited disorders," said Dr. Sean McGhee, clinical instructor of pediatric immunology at Mattel Children's Hospital at UCLA. "Treatment is now advanced enough that 95 percent of children can be cured, but newborns must be detected in the first month, before the onset of severe infections".

Medicineworld.org: Screening Newborn for 'Bubble Boy Disease'

Asthma| Hypertension| Medicine Main| Diab french| Diabetes drug info| DruginfoFrench| Type2 diabetes| Create a dust free bedroom| Allergy statistics| Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.